CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

The CADTH Scientific Advice Program is a voluntary, non-binding, and confidential fee-for-service consultation. Through this Program, pharmaceutical companies are provided with advice on their early drug development plans from a Canadian health technology assessment perspective.

Latest News

Resuming CADTH Scientific Advice Activities

We are pleased to announce that the CADTH Scientific Advice Program will resume activities on October 1, 2020. All Scientific Advice meetings will be held virtually until further notice. Applications for Scientific Advice meetings being planned in late February 2021 and onwards can be submitted online starting October 1, 2020, and will be reviewed for eligibility and availability of meeting dates in the order that they are submitted. Please note that available time periods may fill quickly and CADTH may not be able to accommodate all requests. If you have any questions, please contact scientificadvice@cadth.ca.

Published : October 1, 2020